BioSpace News Archive

TeraPore Technologies, an innovator in nanofiltration membranes, has commercially launched the flagship IsoBlock® VF product line for parvovirus removal from biopharmaceuticals.

Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) announces positive topline results from the Phase II OPALESCENCE investigator-initiated trial (IIT) of its carbonic anhydrase IX (CAIX)-targeting positron emission tomography (PET) imaging candidate, TLX250-CDx (89Zr-DFO-girentuximab), in patients with triple negative breast cancer (TNBC). Results will be presented today at the 2023 San Antonio Breast Cancer Symposium® (SABCS).

MediciNova, Inc. today announced it has received a Notice of Decision to Grant from the European Patent Office for a pending patent application which covers the combination of MN-166 (ibudilast) and interferon-beta for the treatment of progressive multiple sclerosis (progressive MS).

Exai Bio today announced new data demonstrating that its novel RNA-based and AI-driven liquid biopsy platform can detect breast cancer at the earliest stages and the smallest tumor sizes, including ductal carcinoma in situ (DCIS), using a standard blood sample.

Innovent Biologics, Inc. announces the licensing deal expansion with Synaffix B.V., a Lonza company focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates with best-in-class therapeutic index.

Teva Pharmaceutical Industries Ltd. announces that a post hoc analysis4 of two phase 3 clinical studies presented at the European Headache Congress has shown the effectiveness of the migraine prevention treatment AJOVY® in reducing migraine attacks in patients with migraine and co-morbid obesity.

Medivir AB, a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announces that the company will present at the Carlsquare Equity Research Investor Day, December 6, 2023.

Sosei Group Corporation, notes its partner Neurocrine Biosciences Inc., a leading neuroscience-focused biopharmaceutical company, has confirmed its plans to evaluate two new muscarinic agonist candidates in Phase 1 first-in-human clinical studies.

Coherus BioSciences, Inc., announced data from the ongoing Phase 1b/2 clinical trial of casdozokitug, a first-in-class IL-27-targeting antibody, being presented at the 2023 ESMO Immuno-Oncology Congress taking place December 6 – 8, 2023 at Palexpo Exhibition Centre in Geneva, Switzerland.

Antengene Corporation Limited announced that the Pharmaceutical Administration Bureau of Macau has approved a New Drug Application for XPOVIO®.